Abstract
This chapter aims to provide a historical perspective of the Chiroscience matrix metalloproteinase inhibitor (MMPI) program, including the medicinal chemistry strategy which culminated in the clinical candidates D 1927 and D2163. We shall focus on the design of substrate-based inhibitors utilizing a novel zinc-binding group, and the discovery of novel MMPIs that display selectivity for the matrix metalloproteinases (MMPs) over the related metalloproteinase enzymes that mediate cellular shedding events will be reviewed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Beeley NRA, Ansell PRJ, Docherty AJP. Inhibitors of matrix metalloproteinases (MMPs). Curr Opin Ther Patents 1994; 4: 7–16.
Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of antitumour activity. Annals of Oncology 1995; 6: 967–974.
Stetler-Stevenson WG. 1997. Matrix metalloprotease inhibitors, in Cancer Therapeutics: Experimental and Clinical Agents ( Teicher, B., ed), Humana, Totowa, NJ, pp. 241–261.
Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM, Woolley K. Processing of tumour necrosis factor-a precursor by metalloproteinases. Nature 1994; 370: 555–557.
Mousa SA. Mechanisms of angiogenesis in vascular disorders: potential therapeutic targets. Drugs of the Future 1998; 23: 51–60.
Bird J, De Mello RC, Harper GP, Hunter DJ, Karran EH, Markwell, RE, Miles-Williams AJ, Rahman SS, Ward RW. Synthesis of novel N-phosphonoalkyl dipeptide inhibitors of human collagenase. J Med Chem 1994; 37: 158–169.
Porter JR, Millican TA, Morphy JR. Recent developments in matrix metalloproteinase inhibitors. Exp Opin Ther Patents 1995; 5: 1287–1296.
Stams T, Spurlino JC, Smith DL, Wahl RC, Ho TF, Qoronfleh MW, Banks TM, Rubin B. Structure of human neutrophil collagenase reveals large 51’ specificity pocket. Nature Struct Biol 1994; 1: 119–123.
Wyvratt MJ, Patchett AA. Recent developments in the design of angiotensin-converting enzyme inhibitors. Med Res Rev 1985; 5: 483–531.
Baxter AD, Bird J, Bhogal R, Massil T, Minton KJ, Montana J, Owen DA. A novel series of matrix metalloproteinase inhibitors for the treatment of inflammatory disorders. BioMed Chem Lett 1997; 7: 897–902.
Baxter AD, Bhogal R, Bird JB, Buckley GM, Gregory DS, Hedger PC, Manallack DT, Massil T, Minton KJ, Montana JG, Neidle S, Owen DA, Watson RJ. Mercaptoacyl matrix metalloproteinase inhibitors: the effect of substitution at the mercaptoacyl moiety. BioMed Chem Lett 1997; 7: 2765–2770.
Lovejoy B, Hassell AM, Luther MA, Weigl D, Jordan SR. Crystal structures of recombinant 19kDa human fibroblast collagenase complexed to itself. Biochemistry 1994; 33 (27): 8207–8217.
Gomis-Ruth FX, Maskos K, Betz M, Bergner A, Huber R, Suzuki K, Yoshida N, Nagase H, Brew K, Bourenkov GP, Bartunik H, Bode W. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 1997; 389 (6646), 77–81.
Brown P (1994). Inhibitors of matrix metalloproteinases, at SCI Fine Chemicals Group Symposium, New Horizons in Anti-inflammatory Therapy. 11th May 1994, Scientific Societies Lecture Theatre, New Burlington Place, London, WI.
Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat. Cancer Research 1996; 56 (12), 2815–2822.
Drummond AH, Beckett P, Bone EA. BB-2516: an orally bioavailable matrix metalloproteinase inhibitor with efficacy in animal cancer models. Proc Am Assoc Cancer Res 1995; 36: 100 (abstract).
Millar A, Parsons S, Primrose J, Poole C, Evans J 1996. Phase II clinical trials of marimastat. Proceedings of the 21st Congress of the European Society for Medical Oncology, Vienna, Austria.
Wojtowicz-Praga S, Torri J, Johnson M, Steen V, Marshall J, Ness E, Dickson R, Sale M, Rasmussen HS, Chiodo TA, Hawkins MJ. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncology 1998; 16: 2150–2156.
Lombard MA, Wallace TL, Kubicek MF, Petzold GL, Mitchell MA, Hendges SK, Wilks JW. Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-a receptors in a human colon adenocarcinoma (Colo 205) cell line. Cancer Res 1998; 58: 4001–4007.
McGeehan GM, Becherer JD, Bast RC, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S, McElroy AB, Nichols J, Pryzwansky KM, Schoenen F, Sekut L, Truesdale A, Verghese M, Warner J, Ways JP. Regulation of tumour necrosis factor-a processing by a metalloproteinase inhibitor. Nature 1994; 370: 558–561.
Williams LM, Gibbons DL, Gearing A, Maini RN, Feldmann M, Brennan FM. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures. J Clin Invest 1996; 97: 2833–2841.
Tiffen P and Adger B, Tetrahedron Letters 1997; 38: 2153.
von Geldern TW, Hoffman DJ, Kester JA, Nellans HN, Dayton BD, Calzadilla SV, Marsh KC, Hernendez L, Chiou W, Dixon DB, Wu-Wong JR, Opgenorth TJ. Azole endothelin antagonists 3: Using D log Pas a tool to improve absorption J. Med. Chem. 1996; 39, 982–991.
Drummond AH. Paper given at the CHI conference on ‘Protease inhibitors: new therapeutics and approaches’. Baltimore, USA, November 1996.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Baxter, A.D. et al. (2001). D1927 and D2163. In: Clendeninn, N.J., Appelt, K. (eds) Matrix Metalloproteinase Inhibitors in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-011-7_8
Download citation
DOI: https://doi.org/10.1007/978-1-59259-011-7_8
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-123-3
Online ISBN: 978-1-59259-011-7
eBook Packages: Springer Book Archive